Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU)

Key Points

• Radiotherapy combined with nivolumab and ipilimumab shows promise for advanced esophageal cancer treatment.
• Primary endpoint focuses on assessing treatment efficacy in adult patients with recurrent esophageal cancer.
• Randomized controlled trial protocol registered under Japan Clinical Oncology Group study JCOG2311.
• Support for exploring innovative therapies may enable improved outcomes in esophageal cancer patients.

Abstract